Acasti Pharma traded at $2.37 this Thursday June 25th, increasing $0.04 or 1.72 percent since the previous trading session. Looking back, over the last four weeks, Acasti Pharma gained 0.42 percent. Over the last 12 months, its price fell by 19.39 percent. Looking ahead, we forecast Acasti Pharma to be priced at 2.33 by the end of this quarter and at 2.18 in one year, according to Trading Economics global macro models projections and analysts expectations.
Acasti Pharma Inc. is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The Company's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The Company's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.